The study indicated that DPEP1 can be used as an independent predictor of prognosis in patients with RCC, and is expected to be used as a target of immunotherapy, providing a new avenue for the immunotherapy of renal cancer (Ren et al., 2021). Here, DPEP1 is linked to renal cell carcinoma.